Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Inflation, rising interest rates, market volatility, violence in Ukraine and a persistent pandemic created a chaotic macroenvironment for doing business. Pharma appears poised to grow, nonetheless.

second quarter
Pharma is poised to update investors on second quarter results • Source: Shutterstock

When market conditions get choppy, pharmaceutical manufacturers usually float above the fray, but the second quarter of 2022 has certainly put the industry's standard stability to the test. The macroenvironment has delivered one volatile punch after another – inflation, supply constraints, labor shortages, rising US interest rates, a prolonged military conflict in Ukraine and a pandemic that continues to disrupt communities and business operations.

Amidst this turmoil, drug makers are poised to report second quarter sales and earnings, beginning with Johnson & Johnson...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.